Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492956 · ClinicalTrials.gov registry record · Phase 2
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
A Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering), sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 9
- Study locations
NCT04492956 is a Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering) that has completed, run by Emalex Biosciences. The registered enrollment target is 68 participants. The trial reports 9 study locations across 7 states.
The verdict
NCT04492956, a Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering), has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ecopipam
Study Locations (9)
California
- UC Riverside - Riverside
- CI Trials - Santa Ana
Florida
- Clinical Neuroscience Solutions Inc - Jacksonville
- Clinical Neuroscience Solutions Inc - Orlando
Georgia
- Institute For Advanced Medical Research - Atlanta
Kansas
- Social Psychiatry Research Institute - Prairie Village
Michigan
- Michigan State University - East Lansing
New York
- Social Psychiatry Research Institute - Brooklyn
Tennessee
- Clinical Neuroscience Solutions Inc - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04492956
The ClinicalTrials.gov registry entry for NCT04492956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Childhood-Onset Fluency Disorder (Stuttering) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04492956 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04492956 about?
NCT04492956 is a clinical study titled "Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)". This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
What is the current status of trial NCT04492956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2020-10-02. Estimated completion is 2022-04-04.
What conditions does trial NCT04492956 study?
This clinical trial studies the following conditions: Childhood-Onset Fluency Disorder (Stuttering).
What interventions are being tested in trial NCT04492956?
The interventions under investigation include: Placebo (DRUG), Ecopipam (DRUG).
Who is sponsoring clinical trial NCT04492956?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04492956 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.